MedWatch

Abbott spin-out to initiate new study with Danish drug

A candidate drug from the Danish company Action Pharma, which was bought by Abbott for more than 100 million US dollars, will now continue in clinical trials through a spin-out company.

Foto: Abbvie

Action Pharma’s sale of a promising candidate drug to Abbott is on the list of the ten biggest biotech deals in Denmark within the last 5 years, and now the US pharmaceutical group’s million-dollar purchased will continue in clinical phases in the hope that the candidate, AP214, will eventually go all the way to approval.

“We will now initiate phase IIb based on the results created in phase IIa. Denmark is a part of this development program, and we look forward to it. And we are hopeful about future results within this area,” says Christina Horan, CEO of the newly-founded Abbott spin-out, Abbvie.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier